轻度认知障碍患者中被破坏的能量景观:来自网络控制理论的见解
bioRxiv : the preprint server for biology
|July 16, 2025
概括
轻度认知障碍 (MCI) 患者表现出大脑能量格局的改变. 网络控制理论显示,与健康对照组相比,边缘网络的过渡能量较低,MCI的全球性降低.
科学领域:
- 神经科学是一个神经科学.
- 系统生物学 系统生物学
- 医疗成像医学成像
背景情况:
- 轻度认知障碍 (MCI) 是认知衰退的早期阶段,其特点是大脑结构和功能障碍.
- 了解大脑结构和功能之间的相互作用对于开发有效的MCI干预措施至关重要.
- 网络控制理论 (NCT) 提供了一种多模式方法,通过整合功能活动和结构连接来分析大脑能量景观.
研究的目的:
- 调查MCI和健康对照 (HC) 个体之间大脑能量格局的差异.
- 探索MCI中大脑过渡能量 (TE),和神经退行性标记物 (粉样β和) 之间的关系.
主要方法:
- 功能性MRI (fMRI) 和PET成像用于55名MCI患者和499名HC患者.
- 从fMRI数据中,K-means集群识别了来自fMRI数据的重复性脑活动状态.
- 网络控制理论 (NCT) 计算了状态之间的过渡能量 (TE). 测量了,粉样β (Aβ) 和沉积. 线性模型比较了组之间的TE和,并评估了与Aβ和tau的关联.
主要成果:
- 与HC相比,MCI患者在边缘网络中表现出较低的过渡能量 (TE) (调整后p=0.028).
- 在MCI患者中,全球显著降低 (p=7.29e-7).
- 发现TE与前端对称网络中的 (p=7.03e-3) 之间存在正相关性,而增加的全球Aβ与MCI中更高的全球相关 (p=0.041).
结论:
- 下边缘网络TE在MCI中可能反映神经退行或补偿功能上调.
- 改变的大脑能量格局,以减少TE和为特征,在早期认知障碍中很明显.
- 包括阿尔茨海默病 (AD) 患者在内的进一步研究是必要的,以充分描述跨认知衰退阶段的能量景观变化.
更多相关视频
09:01A Method for Investigating Age-related Differences in the Functional Connectivity of Cognitive Control Networks Associated with Dimensional Change Card Sort Performance
Published on: May 7, 2014
10.3K
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
8.0K
相关概念视频
High-Level and Low-Level Awareness
395
Controlled processes in human consciousness represent high-alert mental states where individuals deliberately focus their attention on achieving specific goals. Controlled processes can be seen in situations like mastering new technology, where a person might become so absorbed that they ignore surrounding distractions. Such processes involve selective attention, requiring one to concentrate on particular elements of experience while disregarding others. These are governed by executive...
395
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
212
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
212
